Dr. Paul Nunzio DeSantis, Pharm.D
Event-driven, research analyst, hedge fund analyst, biotech

Intercept Pharmaceuticals (Part II): The Short Story Is Over, Time For The Long Story

Since the publication of "The Short Story of Intercept Pharmaceuticals Part I: A Conference Call With Expert Physicians" on January 12th 2014, Intercept's stock price has declined from $445 per share (January 10th closing price) to $295.5 per share or -33%, although we would note that the stock initially corrected to $235 per share or -47% on January 14th.

Now that the crowd euphoria has faded, we amend our bearish view on Intercept Pharmaceuticals (NASDAQ:ICPT) and currently view it as a compelling asymmetric trading opportunity from the long side based on positive topline Phase 3 POISE data that substantially derisks the FXR pathway in chronic liver diseases and increases our confidence in the pharmacology of OCA....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details